Pregled bibliografske jedinice broj: 13760
Immune response and clinical findings in uveitis, optic neuritis and multiple sclerosis during Peptid-M (Lupex) therapy
Immune response and clinical findings in uveitis, optic neuritis and multiple sclerosis during Peptid-M (Lupex) therapy // First Combined International Symposium on Ocular Immunology and Inflammation : Proceedings / Kijlstra, A. (ur.).
Amsterdam: Aeolus Press, 1998. str. S15-S15 (poster, međunarodna recenzija, cjeloviti rad (in extenso), znanstveni)
CROSBI ID: 13760 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Immune response and clinical findings in uveitis, optic neuritis and multiple sclerosis during Peptid-M (Lupex) therapy
Autori
Štambuk, Nikola ; Brinar, Vesna ; Štambuk, Vjera ; Brzović, Zdravko ; Zurak, Niko ; Marušić-Della Marina, Branka ; Karaman, Ksenija ; Svoboda Beusan, Ivna ; Mažuran, Renata ; Rabatić, Sabina ; Marotti, Tanja ; Šverko, Višnja ; Trbojević-Čepe, Milica ; Rudolf, Maja ; Martinić, Roko ; Malenica, Branko ; Sučić, Zdravko ; Gagro, Alenka ; Pokrić, Biserka
Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), znanstveni
Izvornik
First Combined International Symposium on Ocular Immunology and Inflammation : Proceedings
/ Kijlstra, A. - Amsterdam : Aeolus Press, 1998, S15-S15
Skup
First Combined International Symposium on Ocular Immunology and Inflammation
Mjesto i datum
Amsterdam, Nizozemska, 27.06.1998. - 01.07.1998
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
peptid-M; peptide therapy; anterior uveitis; Behçet's disease; intermediate uveitis; optic neuritis; multiple sclerosis; immunomodulation
Sažetak
Peptid-M is a small molecular mass neuropeptie (PENK, 100-104 aa), present in low quantity in different tissue including thymus. We analysed the results of peptid-M therapy in 21 patients with anterior uveitis, Behçet's disease, intermediate uveitis, optic neuritis and elapsing-remitting multiple sclerosis. Peptid-M (Lupex, Biofactor, Germany) was administered s.c. 0.25 mg/kg 5 times weekly for 4 weeks, then gradually reduced to 0.25 mg/kg weekly devided in 2 doses for >6 months. After peptide-M administration we observed marked rise in serum IFN levels, modulation of phagocite functions, NK activity, serum IL-4 and lowering of CD3+CD16+56 + cells. Clinical amelioration was noticed in all patients with uveitis and optic neuritis and in 10/12 MS patients. Improvements of VEP, colour vision, visual field abnormalities, EDSS and MRI findings were observed in most of the patients.
Izvorni jezik
Engleski
Znanstvena područja
Javno zdravstvo i zdravstvena zaštita, Farmacija
Napomena
Ocular Immunology and Inflammation (0927-3948) 6 (1998) (Suppl.)
POVEZANOST RADA
Ustanove:
Imunološki zavod d.d.,
Institut "Ruđer Bošković", Zagreb
Profili:
Biserka Pokrić
(autor)
Vesna Brinar
(autor)
Nikola Štambuk
(autor)
Ivna Svoboda-Beusan
(autor)
Ksenija Karaman
(autor)
Vjera Štambuk
(autor)
Sabina Rabatić
(autor)
Milica Trbojević-Čepe
(autor)
Roko Martinić
(autor)
Tatjana Marotti
(autor)
Ana-Višnja Šverko
(autor)
Alenka Gagro
(autor)
Zdravko Brzović
(autor)
Branka Marušić-Della Marina
(autor)
Renata Mažuran
(autor)
Branko Malenica
(autor)